Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 3;12(8):2150.
doi: 10.3390/cancers12082150.

The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer

Nicole E James  1 , Morgan Woodman  1 , Paul A DiSilvestro  1   2 , Jennifer R Ribeiro  1   2
Affiliations
Review

The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer

Nicole E James et al. Cancers (Basel). .

Abstract

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, with an overall 5-year survival of only 47%. As the development of novel targeted therapies is drastically necessary in order to improve patient survival, current EOC clinical trials have heavily focused on immunotherapeutic approaches, centered upon programmed cell death 1 (PD-1) inhibitors. While PD-1 monotherapies have only exhibited modest responses for patients, it has been theorized that in order to enhance EOC patient response to immunotherapy, combinatorial regimens must be investigated. In this review, unique challenges to EOC PD-1 response will be discussed, along with a comprehensive description of both preclinical and clinical studies evaluating PD-1-based combinatorial therapies. Promising aspects of PD-1-based combinatorial approaches are highlighted, while also discussing specific preclinical and clinical areas of research that need to be addressed, in order to optimize EOC patient immunotherapy response.

Keywords: PD-1; immunotherapy; ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Preclinical and clinical areas of focus to enhance PD-1-based combinatorial treatment response.
See this image and copyright information in PMC

References

    1. American Cancer Society Cancer Statistics Center—Ovary. [(accessed on 9 April 2020)]; Available online: https://cancerstatisticscenter.cancer.org/#!/cancer-site/Ovary.
    1. Pignata S., Cecere S.C., Du Bois A., Harter P., Heitz F. Treatment of recurrent ovarian cancer. Ann. Oncol. 2017;28(Suppl. 8):viii51–viii56. doi: 10.1093/annonc/mdx441. - DOI - PubMed
    1. Zhu X., Lang J. Programmed death-1 pathway blockade produces a synergistic antitumor effect: Combined application in ovarian cancer. J. Gynecol. Oncol. 2017;28:1093851. doi: 10.3802/jgo.2017.28.e64. - DOI - PMC - PubMed
    1. Ibrahim E.M., Refae A.A., Bayer A.M., Sagr E.R. Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: A meta-analysis. Future Oncol. 2020;16:585–596. doi: 10.2217/fon-2020-0057. - DOI - PubMed
    1. Kerliu L., Myruski S., Bhatti A., Soni P., Petrosius P., Pervanas H.C., Horton E.R. Niraparib for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer [published online ahead of print, 2020 Mar 16] Ann. Pharmacother. 2020:1060028020912749. - PubMed